This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5-H
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately em...
BACKGROUND: Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vom...
Background: Nausea and vomiting remain a problem for children undergoing treatment for malignancies ...
This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the ...
To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in childr...
To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in childr...
This guideline provides an approach to the prevention of acute antineoplastic-induced nausea and vom...
Background: Chemotherapy-induced nausea and vomiting (CINV) is a feared adverse reaction during canc...
Antineoplastic drug induced nausea and vomiting (AINV) is a major adverse event which deeply impacts...
AbstractAntineoplastic drug induced nausea and vomiting (AINV) is a major adverse event which deeply...
Aprepitant is an effective antiemetic for the prevention of acute chemotherapy-induced nausea and vo...
BACKGROUND: Nausea and vomiting are preventable side effects of cancer chemotherapy for children...
Purpose: The purpose of this study was to assess the use of supplemental, as needed (prn) pharmacolo...
To review and update the existing local antiemetic guidelines at the Royal Hospital for Sick Childre...
Our obbjective is to review and update the existing local antiemetic guidelines at the Royal Hospita...
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately em...
BACKGROUND: Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vom...
Background: Nausea and vomiting remain a problem for children undergoing treatment for malignancies ...
This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the ...
To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in childr...
To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in childr...
This guideline provides an approach to the prevention of acute antineoplastic-induced nausea and vom...
Background: Chemotherapy-induced nausea and vomiting (CINV) is a feared adverse reaction during canc...
Antineoplastic drug induced nausea and vomiting (AINV) is a major adverse event which deeply impacts...
AbstractAntineoplastic drug induced nausea and vomiting (AINV) is a major adverse event which deeply...
Aprepitant is an effective antiemetic for the prevention of acute chemotherapy-induced nausea and vo...
BACKGROUND: Nausea and vomiting are preventable side effects of cancer chemotherapy for children...
Purpose: The purpose of this study was to assess the use of supplemental, as needed (prn) pharmacolo...
To review and update the existing local antiemetic guidelines at the Royal Hospital for Sick Childre...
Our obbjective is to review and update the existing local antiemetic guidelines at the Royal Hospita...
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately em...
BACKGROUND: Palonosetron has shown efficacy in the prevention of chemotherapy-induced nausea and vom...
Background: Nausea and vomiting remain a problem for children undergoing treatment for malignancies ...